Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA ‐HF

ConclusionsIn DAPA ‐HF, one‐in‐eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher risk of the primary outcome. The benefit of dapagliflozin on all prespecified outcomes was consistent in patients with and without COPD.

Source: European Journal of Heart Failure - December 23, 2020 Category: Cardiology Authors: Pooja Dewan, Kieran F Docherty, Olof Bengtsson, Rudolf A Boer, Akshay S Desai, Jaroslaw Drozdz, Nathaniel M Hawkins, Silvio E Inzucchi, Masafumi Kitakaze, Lars K øber, Mikail N Kosiborod, Anna M Langkilde, Daniel Lindholm, Felipe A Martinez, Tags: Research Article Source Type: research